|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析显示文摘背景放疗可以提高整个机体对免疫治疗的应答。在Ⅱ期PEMBRO-RT研究和Ⅰ/Ⅱ期MDACC研究中,患有转移性非小细胞肺癌(NSCLC)的患者被随机分配入组,接受免疫治疗(帕博利珠单抗)+放疗联合疗法,或免疫治疗单一疗法。当上述2个研究单独分析时,联合疗法组显示出潜在获益。由于每个研究的样本量较小,缓解率和结局并未显示出统计学意义,然而却有显著的临床获益。因此,本研究进行汇总分析,来判断放疗是否会改善转移性NSCLC患者的免疫治疗应答。方法PEMBRO-RT和MDACC研究纳入标准:患者年龄≥18岁,患有转移性NSCLC,且有≥1处未经放疗照射的病灶,以便进行射野外应答监测。PEMBRO-RT研究纳入曾接受过化疗患者,MDACC研究纳入曾接受过治疗或新诊断患者。2个研究中的患者均未接受过免疫治疗。在PEMBRO-RT研究中患者被等比例随机分配入组,并根据吸烟状态进行分层(分为<10年组和≥10年组)。MDACC研究的患者根据放疗计划可行性被等比例随机分配入2个受试组。由于联合治疗组的干预本质,每个研究中的放疗均不适用盲法。在2个研究中,不论是否进行放疗,均静脉滴入帕博利珠单抗(每3周200 mg)。在PEMBRO-RT研究中,在放疗(24 Gy 3次分割照射)结束后1周给予第1剂帕博利珠单抗。在MDACC研究中,在第1次放疗(50 Gy 4次分割照射或45 Gy 15次分割照射)同时给予帕博利珠单抗。仅检测未经照射病灶的应答。本研究的终点为最佳射野外(远隔)应答率(ARR)、最佳射野外疾病控制率(ACR)、12周时ARR、12周时ACR、无进展生存期(PFS)和总生存期(OS)。2个研究的意向治疗(ITT)人群均纳入分析。PEMBRO-RT研究(NCT02492568)和MDACC研究(NCT02444741)均在ClinicalTrials.gov上注册。发现纳入148例患者,76例接受帕博利珠单抗治疗,72例接受帕博利珠单抗+放疗治疗。所有患者随访时间中位数为33个月[四分位距(IQR):32.4~33.6]。148例患者中124例(84%)组织学特征为非鳞癌,111例(75%)患者曾经接受过化疗。组间没有基线特征差异,包括PD-L1表达状态和转移灶体积。最常见的照射部位为肺转移灶(39%,28/72)、胸腔内淋巴结(21%,15/72)和非原发灶(17%,12/72)。帕博利珠单抗组和联合治疗组的最佳ARR分别为19.7%(15/76)和41.7%(30/72),OR=2.96,95%CI:1.42~6.20,P=0.0039;最佳ACR分别为43.4%(33/76)和65.3%(47/72),OR=2.51,95%CI:1.28~4.91,P=0.0071;PFS中位数分别为4.4(IQR:2.9~5.9)和9.0个月(IQR:6.8~11.2),HR=0.67,95%CI:0.45~0.99,P=0.045;OS中位数分别为8.7(IQR:6.4~11.0)和19.2个月(IQR:14.6~23.8),OR=0.67,95%CI:0.54~0.84,P=0.0004。在汇总分析中没有发现新的安全问题。解读帕博利珠单抗免疫疗法+放疗显著提高转移性NSCLC患者的应答和改善治疗结局。这些结果需要在三期临床试验中进行验证。 | 陈大卫(翻译) 于金明(校对) Willemijn S M E Theelen Vivek Verma Brian P Hobbs Heike M U Peulen Joachim G J V Aerts Idris Bahce Anna Larissa N Niemeijer Joe Y Chang Patricia M de Groot Quynh-Nhu Nguyen Nathan I Comeaux George R Simon Ferdinandos Skoulidis Steven H Lin Kewen He Roshal Patel John Heymach Paul Baas James W Welsh | 2021 | 中华肿瘤防治杂志2021，28，24： | 49 |
| 2 | Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis显示文摘AIM:To determine if subclinical abnormal glucose tolerance(SAGT)has influence on survival of non-diabetic patients with liver cirrhosis.METHODS:In total,100 patients with compensatedliver cirrhosis and normal fasting plasma glucose were included.Fasting plasma insulin(FPI)levels were measured,and oral glucose tolerance test(OGTT)was performed.According to OGTT results two groups of patients were formed:those with normal glucose tolerance(NGT)and those with SAGT.Patients were followed every three months.The mean follow-up was932 d(range of 180-1925).Survival was analyzed by the Kaplan-Meyer method,and predictive factors of death were analyzed using the Cox proportional hazard regression model.RESULTS:Of the included patients,30 showed NGT and70 SAGT.Groups were significantly different only in age,INR,FPI and HOMA2-IR.Patients with SAGT showed lower 5-year cumulated survival than NGT patients(31.7%vs 71.6%,P=0.02).Differences in survival were significant only after 3 years of follow-up.SAGT,Child-Pugh B,and high Child-Pugh and Model for EndStage Liver Disease(MELD)scores were independent predictors of death.The causes of death in 90.3%of cases were due to complications related to liver disease.CONCLUSION:SAGT was associated with lower survival.SAGT,Child-Pugh B,and high Child-Pugh and MELD scores were independent negative predictors of survival. | Diego García-Compeán Joel Omar Jáquez-Quintana Fernando Javier Lavalle-González José Alberto González-González Linda Elsa Mu?oz-Espinosa Jesús Zacarías Villarreal-PérezEndocrinology Service and Department of Internal Medicine University Hospital 'Dr. José E. González' and Medical School Universidad Autónoma de Nuevo León Monterrey 64320 México Héctor J Maldonado-Garza | 2014 | World Journal of Gastroenterology2014，20，22： | 12 |
| 3 | 固定低剂量三联抗高血压药物与常规治疗对斯里兰卡轻度至中度高血压患者血压控制的疗效差异:一项随机临床试验显示文摘控制不良的高血压是全球领先的公共卫生问题,需要新的治疗策略。该研究评估低剂量三联抗高血压药物治疗是否能达到比常规治疗更好的血压控制。研究者纳入2016年2月至2017年5月在斯里兰卡11所城市医院诊所就诊的需要开始抗高血压治疗(未治疗的患者)或接受单药治疗的患者,进行低剂量三联降压与常规治疗比较的随机、开放性试验,随访至2017年10月。 | Web-ster R Salam A de Silva HA Selak V Stepien S Rajapakse S Amarasekara S Amarasena N Billot L de Silva AP Fernando M Guggilla R Jan S Jayawardena J Maulik PK Mendis S Munasinghe J Naik N Prabhakaran D Ranasinghe G Thom S Tisserra N Senaratne V Wijekoon S Wijeyasingam S Rodgers A Patel A 刘莉 叶鹏 | 2018 | 中华高血压杂志2018，26，12： | 7 |
| 4 | TAT-Gap19通过抑制啮齿动物星形胶质细胞的连接蛋白43半通道发挥抗惊厥作用显示文摘越来越多的证据表明,星形胶质细胞连接蛋白43(Cx43)信号在癫痫中发挥至关重要的作用。但是,由于通过实验方法鉴别Cx43间隙连接通道(GJCs)和半通道(HCs)的技术尚不成熟,导致目前尚无法确定哪个通道在癫痫的发生中发挥更重要的作用。因此,本研究观察TAT-Gap19(Cx模拟肽)是否通过抑制Cx43半通道而非Cx43间隙连接通道影响实验诱导的啮齿动物癫痫发作。急性海马切片小鼠染料摄取实验表明,星形胶质Cx43半通道响应化学惊厥毛果芸香碱的作用而开放,并且可被TAT-Gap19抑制。体内实验中,毛果芸香碱诱导的癫痫发作及相伴随的D-丝氨酸微透析液的增长水平被Cx43半通道的抑制所抑制。此外,TAT-Gap19的抗惊厥作用被外源性D-丝氨酸给药逆转,这表明,抑制Cx43半通道可以通过降低细胞外D-丝氨酸水平来防止癫痫发作。抑制Cx43半通道的抗惊厥特性在电癫痫小鼠模型(如急性6 Hz难治性癫痫发作模型和慢性6 Hz角膜点燃模型)中得到了进一步的证实。总而言之,这些结果表明,Cx43半通道在癫痫发作中可以起到一定作用,并且有成为癫痫治疗中新型用药靶点的潜力。 | Walrave L Pierre A Albertini G Aourz N De Bundel D Van Eeckhaut A Vinken M Giaume C Leybaert L Smolders I 聂昊 | 2018 | 神经损伤与功能重建2018，13，6： | 5 |
| 5 | Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?显示文摘Chronic hepatitis B(CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue(NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B virus(HBV) infection. The accepted endpoint for therapy is the loss of hepatitis B surface antigen(HBs Ag), but this is hardly ever achieved. Therefore, indefinite treatment is usually required. Many different studies have evaluated NA therapy discontinuation after several years of NA treatment and before HBs Ag loss. The results have indicated that the majority of patients can remain off therapy, with some even reaching HBs Ag seroconversion. Fortunately, this strategy has proved to be safe, but it is essential to consider the risk of liver damage and other comorbidities and to ensure aclose follow-up of the candidates before considering this strategy. Unanswered questions remain, namely in which patients could this strategy be effective and what is the optimal time point at which to perform it. To solve this enigma, we should keep in mind that the outcome will ultimately depend on the equilibrium between HBV and the host's immune system. Viral parameters that have been described as good predictors of response in HBe Ag(+) cases, have proven useless in HBe Ag(-) ones. Since antiviral immunity plays an essential role in the control of HBV infection, we sought to review and explain potential immunological biomarkers to predict safe NA discontinuation in both groups. | Elia Moreno-Cubero Robert T Sánchez del Arco Julia Pena-Asensio Eduardo Sanz de Villalobos Joaquín Míquel Juan Ramón Larrubia | 2018 | World Journal of Gastroenterology2018，24，17： | 5 |
| 6 | Fecal immunochemical test accuracy in average-risk colorectal cancer screening显示文摘AIM:To assess the fecal immunochemical test(FIT)accuracy for colorectal cancer(CRC)and advanced neoplasia(AN)detection in CRC screening.METHODS:We performed a multicentric,prospective,double blind study of diagnostic tests on asymptomatic average-risk individuals submitted to screening colonoscopy.Two stool samples were collected and the fecal hemoglobin concentration was determined in the first sample(FIT1)and the highest level of both samples(FITmax)using the OC-sensor.Areas under the curve(AUC)for CRC and AN were calculated.The best FIT1and FITmax cut-off values for CRC were determined.At this threshold,number needed to scope(NNS)to detect a CRC and an AN and the cost per lesion detected were calculated.RESULTS:About 779 individuals were included.An AN was found in 97(12.5%)individuals:a CRC in 5(0.6%)and an advanced adenoma(≥10 mm,villous histology or high grade dysplasia)in 92(11.9%)subjects.For CRC diagnosis,FIT1 AUC was 0.96(95%CI:0.95-0.98)and FITmax AUC was 0.95(95%CI:0.93-0.97).For AN,FIT1 and FITmax AUC were similar(0.72,95%CI:0.66-0.78 vs 0.73,95%CI:0.68-0.79,respectively,P=0.34).Depending on the number of determinations and the positivity threshold cut-off used sensitivity for AN detection ranged between 28%and 42%and specificity between 91%and 97%.At the best cut-off point for CRC detection(115 ng/mL),the NNS to detect a CRC were 10.2 and 15.8;and the cost per CRC was 1814€and 2985€on FIT1 and FITmax strategies respectively.At this threshold the sensitivity,NNS and cost per AN detected were 30%,1.76,and 306€,in FIT1 strategy,and 36%,2.26€and 426€,in FITmax strategy,respectively.CONCLUSION:Performing two tests does not improve diagnostic accuracy,but increases cost and NNS to detect a lesion. | Vicent Hernandez Joaquin Cubiella M Carmen Gonzalez-Mao Felipe Iglesias Concepción Rivera M Begoa Iglesias Lucía Cid Ines Castro Luisa de Castro Pablo Vega Jose Antonio Hermo Ramiro Macenlle Alfonso Martínez-Turnes David Martínez-Ares Pamela Estevez Estela Cid M Carmen Vidal Angeles López-Martínez Elisabeth Hijona Marta Herreros-Villanueva Luis Bujanda Jose Ignacio Rodriguez-Prada the COLONPREV study investigators | 2014 | World Journal of Gastroenterology2014，20，4： | 4 |
| 7 | 补体B因子是代谢综合征模型代谢与心血管特征的一个决定因素显示文摘补体B因子(complenment factor B,CFB)在2型糖尿病及心血管病患者脂肪组织及血清中水平升高,但与疾病发病机制的因果关系不明确。自发性高血压大鼠(spontaneously hypertensive rats,SHR)脂肪组织及血清中CFB也升高。为明确CFB在代谢综合征中的作用,研究者在SHR中敲除Cfb基因。 | 赵狄 练桂丽 Coan PM Barrier M Alfazema N Carter RN Marion de Procé S Dopico XC Garcia Diaz A Thomson A Jackson-Jones LH Moyon B Webster Z Ross D Moss J Arends MJ Morton NM Aitman TJ | 2017 | 中华高血压杂志2017，25，8： | 3 |
| 8 | Langerhans cell histiocytosis masquerading as acute appendicitis: Case report and review显示文摘Langerhans cell histiocytosis(LCH) is a rare syndrome characterized by unifocal,multifocal unisystem,or disseminated/multi-system disease that commonly involves the bone,skin,lymph nodes,pituitary,or sometimes lung(almost exclusively in smokers) causing a variety of symptoms from rashes and bone lesions to diabetes insipidus or pulmonary infiltrates.We present a previously unreported case of gastrointestinal LCH as well as a novel characteristic lesion affecting the colon of a young woman who presented with signs and symptoms mimicking acute on chronic appendicitis.Immunohistochemical analysis of appendectomy specimen and nodular specimens on colonoscopy demonstrated S-100,CD1a,and langerin reactivity.The patient underwent systemic chemotherapy with cytarabine and demonstrated excellent response to therapy. | Mohammad M Karimzada Michele N Matthews Samuel W French Daniel De Ugarte Dennis Y Kim | 2017 | World Journal of Gastrointestinal Endoscopy2017，9，3： | 3 |
| 9 | Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype显示文摘 | Anna Abulí Xavier Bessa Juan Ramón González Clara Ruiz–Ponte Alejandro Cáceres Jenifer Mu?oz Victoria Gonzalo Francesc Balaguer Ceres Fernández–Rozadilla Dolors González Luisa de Castro Juan Clofent Luís Bujanda Joaquín Cubiella Josep M a Re?é Juan Diego | 2010 | Gastroenterology2010，，3： | 2 |
| 10 | Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection显示文摘Severe Acute Respiratory Syndrome Coronavirus(SARS-CoV)-2 infection induces an exacerbated inflammation driven by innate immunity components.Dendritic cells(DCs)play a key role in the defense against viral infections,for instance plasmacytoid DCs(pDCs),have the capacity to produce vast amounts of interferon-alpha(IFN-α).In COVID-19 there is a deficit in DC numbers and IFN-αproduction,which has been associated with disease severity.In this work,we described that in addition to the DC deficiency,several DC activation and homing markers were altered in acute COVID-19 patients,which were associated with multiple inflammatory markers.Remarkably,previously hospitalized and nonhospitalized patients remained with decreased numbers of CD1c+myeloid DCs and pDCs seven months after SARS-CoV-2 infection.Moreover,the expression of DC markers such as CD86 and CD4 were only restored in previously nonhospitalized patients,while no restoration of integrinβ7 and indoleamine 2,3-dyoxigenase(IDO)levels were observed.These findings contribute to a better understanding of the immunological sequelae of COVID-19. | Alberto Pérez-Gómez Joana Vitallé Carmen Gasca-Capote Alicia Gutierrez-Valencia María Trujillo-Rodriguez Ana Serna-Gallego Esperanza Muñoz-Muela María de los Reyes Jiménez-Leon Mohamed Rafii-El-Idrissi Benhnia Inmaculada Rivas-Jeremias Cesar Sotomayor Cristina Roca-Oporto Nuria Espinosa Carmen Infante-Domínguez Juan Carlos Crespo-Rivas Alberto Fernández-Villar Alexandre Pérez-González Luis Fernando López-Cortés Eva Poveda Ezequiel Ruiz-Mateos JoséMiguel Cisneros Sonsoles Salto-Alejandre Judith Berastegui-Cabrera Pedro Camacho-Martínez Carmen Infante-Domínguez Marta Carretero-Ledesma Juan Carlos Crespo-Rivas Eduardo Márquez JoséManuel Lomas Claudio Bueno Rosario Amaya JoséAntonio Lepe Jerónimo Pachón Elisa Cordero Javier Sánchez-Céspedes Manuela Aguilar-Guisado Almudena Aguilera Clara Aguilera Teresa Aldabo-Pallas Verónica Alfaro-Lara Cristina Amodeo Javier Ampuero María Dolores Avilés Maribel Asensio Bosco Barón-Franco Lydia Barrera-Pulido Rafael Bellido-Alba Máximo Bernabeu-Wittel Candela Caballero-Eraso Macarena Cabrera Enrique Calderón Jesús Carbajal-Guerrero Manuela Cid-Cumplido Yael Corcia-Palomo Juan Delgado Antonio Domínguez-Petit Alejandro Deniz Reginal Dusseck-Brutus Ana Escoresca-Ortega Fátima Espinosa Nuria Espinosa Michelle Espinoza Carmen Ferrándiz-Millón Marta Ferrer Teresa Ferrer Ignacio Gallego-Texeira Rosa Gámez-Mancera Emilio García Horacio García-Delgado Manuel García-Gutiérrez María Luisa Gascón-Castillo Aurora González-Estrada Demetrio González Carmen Gómez-González Rocío González-León Carmen Grande-Cabrerizo Sonia Gutiérrez Carlos Hernández-Quiles Inmaculada Concepción Herrera-Melero Marta Herrero-Romero Luis Jara Carlos Jiménez-Juan Silvia Jiménez-Jorge Mercedes Jiménez-Sánchez Julia Lanseros-Tenllado Carmina López Isabel López Álvaro López-Barrios Luis F.López-Cortés Rafael Luque-Márquez Daniel Macías-García Guillermo Martín-Gutiérrez Luis Martín-Villén JoséMolina Aurora Morillo María Dolores Navarro-Amuedo Dolores Nieto-Martín Francisco Ortega María Paniagua-García Amelia Peña-Rodríguez Esther Pérez Manuel Poyato Julia Praena-Segovia Rafaela Ríos Cristina Roca-Oporto Jesús F.Rodríguez María Jesús Rodríguez-Hernández Santiago Rodríguez-Suárez Ángel Rodríguez-Villodres Nieves Romero-Rodríguez Ricardo Ruiz Zida Ruiz de Azua Celia Salamanca Sonia Sánchez Víctor Manuel Sánchez-Montagut César Sotomayor Alejandro Suárez Benjumea Javier Toral | 2021 | Cellular & Molecular Immunology2021，18，9： | 2 |
| 11 | Advances and new perspectives in the treatment of metastatic colon cancer显示文摘During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new'standards of care'are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease. | Gonzalo Recondo Jr Enrique Díaz-Cantón Máximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Gastrointestinal Oncology2014，6，7： | 2 |
| 12 | Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions显示文摘AIM To investigate the main current etiologies of cirrhosis in Mexico.METHODS We performed a cross-sectional retrospective multicenter study that included eight hospitals in different areas of Mexico. These hospitals provide health care to people of diverse social classes. The inclusion criteria were a histological, clinical, biochemical, endoscopic, or imaging diagnosis of liver cirrhosis. Data were obtained during a 5-year period(January 2012-December 2017). RESULTS A total of 1210 patients were included. The mean age was 62.5 years(SD = 12.1), and the percentages of men and women were similar(52.0% vs 48.0%). The most frequent causes of liver cirrhosis were hepatitis C virus(HCV)(36.2%), alcoholic liver disease(ALD)(31.2%), and nonalcoholic steatohepatitis(23.2%), and the least frequent were hepatitis B virus(1.1%), autoimmune disorders(7.3%), and other conditions(1.0%).CONCLUSION HCV and ALD are the most frequent causes of cirrhosis in Mexico. However, we note that non-alcoholic fatty liver disease(NAFLD) as an etiology of cirrhosis increased by 100% compared with the rate noted previously. We conclude that NAFLD will soon become one of the most frequent etiologies of liver cirrhosis in Mexico. | Nahum Méndez-Sánchez Felipe Zamarripa-Dorsey Arturo Panduro Emma Purón-González Edgar Ulises Coronado-Alejandro Carlos Alejandro Cortez-Hernández Fátima Higuera de la Tijera José Luis Pérez-Hernández Eira Cerda-Reyes Heriberto Rodríguez-Hernández Vania César Cruz-Ramón Oscar Lenin Ramírez-Pérez Nancy Edith Aguilar-Olivos Olga Fabiola Rodríguez-Martínez Samantha Cabrera-Palma Guillermo Cabrera-álvarez | 2018 | World Journal of Clinical Cases2018，6，15： | 2 |
| 13 | 益生菌抑制自发性高血压大鼠的菌群失调和血压升高:短链脂肪酸的作用显示文摘该研究旨在评估益生菌短双歧杆菌CECT7263(BFM)及发酵乳酸杆菌CECT5716(LC40)、短链脂肪酸丁酸盐及醋酸盐对自发性高血压大鼠(spontaneously hypertensive rat,SHR)心血管的作用。方法和结果:5周龄的Wistar Kyoto大鼠(WKY)10只和周龄匹配的SHR 50只随机分为6组:对照WKY、对照SHR、BFM干预的SHR、LC40干预的SHR、丁酸盐干预的SHR和醋酸盐干预的SHR。 | 袁源(译) 练桂丽(审校) Robles-Vera I Toral M de la Visitación N Sánchez M Gómez-Guzmán M Romero M Yang T Izquierdo-Garcia JL Jiménez R Ruiz-Cabello J Guerra-Hernández E Raizada MK Pérez-Vizcaíno F Duarte J | 2020 | 中华高血压杂志2020，28，9： | 2 |
| 14 | 遗传性肥胖与心房颤动的关系显示文摘观察性研究已经确定了体质量指数(body mass index,BMI)与心房颤动之间的关联。然而,从观察性研究中推断因果关系会受到混杂因素、逆因果关系和偏倚的影响。该研究的主要目的是应用BMI的遗传学预测因子评估BMI与心房颤动之间的因果关系。方法:纳入1987-2002年期间在美国、冰岛和荷兰实施的7个前瞻性人群队列研究中基线无心房颤动的欧洲血统个体51 646人, | 刘莉 叶鹏 Chatterjee NA Giulianini F Geelhoed B Lunetta KL Misialek JR Niemeijer MN Rienstra M Rose LM Smith AV Arking DE Ellinor PT Heeringa J Lin H Lubitz SA Soliman EZ Verweij N Alonso A Benjamin EJ Gudnason V Stricker BH van der Harst P Chasman DI Albert CM | 2017 | 中华高血压杂志2017，25，2： | 2 |
| 15 | Aqueous extract of Ocimum tenuiflorum decreases levels of blood glucose in induced hyperglycemic tilapia(Oreochromis niloticus)显示文摘Objective:To evaluate,in hyperglycemic tilapia[Oreochromis niloticus(O.niloticus)].the effect of this aqueous extract on blood glucose levels.Methods:The hyperglycemia in O.niloticus was induced by adding glucose to fish pond water.An aqueous extract of Ocimum tenuiflorum (O.tenuiflorum) was prepared by boiling fresh leaves and the doses of 0,40,80,200 and 400 mg per liter of pond water were tested.Results:The blood sugar concentration for tilapia with hyperglycemic induced was an average of 50%higher than the control group.The blood glucose levels in tilapia after the induction of hyperglycemia were higher than the control group for 90 min after the treatment.The treatment with the aqueous extract of O.tenuiflorum dropped the serum glucose level of hyperglycemic tilapia until it was similar to that of the control group and was dose dependent.Conclusions:The results indicated that O.tenuiflorum was endowed with anti-hyperglycemic activity.To our knowledge,this is the first report on the use of fish as a diabetes model to test natural extracts from plants. | Amilcar Arenal Leonardo Martín Nestor M Castillo Dainier de la Torre Ubaldo Torres Reinaldo Gonzlez | 2012 | Asian Pacific Journal of Tropical Medicine2012，5，8： | 2 |
| 16 | A hysteretic model for a vanadium dioxide transitionedge microbolometer显示文摘 | de Almeida L A L L Deep G S Lima A M N | 2001 | IEEE Trans Instrum Meas2001，50，4： | 2 |
| 17 | 生长兔日粮中棕榈仁粕的营养价值显示文摘为确定饲料中的棕榈仁粕(PKM)对生长兔的营养价值,在试验1中,选用新西兰×加州50日龄生长兔20只来确定PKM的能量、粗蛋白、纤维和脂肪消化率。通过不同方法对其营养价值进行评估,试验分为对照组(基础日粮)和试验组(在基础日粮中添加PKM200g.kg-1)。PKM的能量、粗蛋白、乙醚提取物和中性洗涤纤维的消化率分别为0.549(±0.056,SE)、0.541(±0.069)、0.850(±0.048)和0.430(±0.101),可消化的能量为10.9±1.03MJ.kg-1DM;试验2中,412只生长兔被随机分配在2个试验日粮组来衡量其增长性能。试验结果表明,与对照组相比,PKM日粮组对饲料及可消化能量的摄入无显著差异,但平均日增重(P=0.003)和饲料效率(P<0.001)略有下降(约5%),死亡率和软粪便中产气荚膜梭菌数量都不受日粮类型的影响。说明棕榈仁粕可以作为生长兔的纤维、蛋白质和脂肪来源,其可以替代其他日粮中大量的纤维成分,并且对生产性能没有不利影响。 | Carrión S De Blas J C Méndez J Caídas A García-Rebollar P | 2012 | 饲料博览2012，，2： | 2 |
| 18 | MicroRNAs in biliary diseases显示文摘Cholangiopathies are a group of diseases primarily or secondarily affecting bile duct cells, and result in cholangiocyte proliferation, regression, and/or transformation. Their etiopathogenesis may be associated with a broad variety of causes of different nature, which includes genetic, neoplastic, immune-associated, infectious, vascular, and drug-induced alterations, or being idiopathic. miRNAs, small non-coding endogenous RNAs that post-transcriptionally regulate gene expres sion, have been associated with pathophysiological processes in different organs and cell types, and are postulated as potential targets for diagnosis and therapy. In the current manuscript, knowledge regarding the role of miRNAs in the development and/or progression of cholangiopathies has been reviewed and the most relevant findings in this promising field of hepatology have been highlighted. | Patricia Munoz-Garrido Maite García-Fernández de Barrena Elizabeth Hijona Miguel Carracedo JoséJ G Marín Luis Bujanda Jesús M Banales | 2012 | World Journal of Gastroenterology2012，18，43： | 2 |
| 19 | Competition between fusion-evaporation and multifragmentation in central collisions in ^(58)Ni+^(48)Ca at 25A MeV显示文摘The experimental data concerning the58Ni+48Ca reaction at Elab(Ni)=25A MeV,collected by using the CHIMERA 4π device,have been analyzed in order to investigate the competition among different reaction mechanisms for central collisions in the Fermi energy domain.As a main criterion for centrality selection we have chosen the flow angle(flow) method,making an event-by-event analysis that considers the shape of events,as it is determined by the eigenvectors of the experimental kinetic-energy tensor.For the selected central events(flow >60°) some global variables,good to characterize the pattern of central collisions have been constructed.The main features of the reaction products were explored by using different constraints on some of the relevant observables,like mass and velocity distributions and their correlations.Much emphasis was devoted,for central collisions,to the competition between fusion-evaporation processes with subsequent identification of a heavy residue and a possible multifragmentation mechanism of a well defined(if any) transient nuclear system.Dynamical evolution of the system and pre-equilibrium emission were taken into account by simulating the reactions in the framework of transport theories.Different approaches have been envisaged(dynamical stochastic BNV calculations + sequential SIMON code,QMD,CoMD,etc.).Preliminary comparison of the experimental data with BNV calculations shows reasonable agreement with the assumption of sequential multifragmentation emission in the mass region of IMFs close to the heavy residues.Possible deviations from sequential processes were found for those IMFs in the region of masses intermediate between the mass of heavy residues and the mass of light IMFs.Further simulations are in progress.The experimental analysis will be enriched also by information obtained inspecting the IMF-IMF correlation function,in order to elucidated the nature of space-time decay property of the emitting source associated with events having the largest IMF multiplicity. | FRANCALANZA L ABBONDANNO U AMORINI F BARLINI S BINI M BOUGAULT R BRUNO M CARDELLA G CASINI G AGOSTINO M D' De FILIPPO V De SANCTIS J GERACI E GIUSSANI A GRAMEGNA F GUIOT B KRAVCHUK V La GUIDARA E LANZALONE G Le NEINDRE N MAIOLINO C MARINI P MORELLI L OLMI A PAGANO A PAPA M PIANTELLI S PIRRONE S POLITI G POGGI G PORTO F RUSSOTTO P RIZZO F VANNINI G VANNUCCI L | 2013 | Nuclear Science and Techniques2013，24，5： | 2 |
| 20 | Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers显示文摘瞄准:分析在肝的 anti-HBs 的存在是否移植接受者在阻止 HBV 感染是有效的。方法:23 个病人收到 anti-HBc 积极的肝被学习。九个接受者是由于以前的 HBV 感染积极的 anti-HBc。他们,一个人也收到了在肝前移植时期期间疫苗的 HBV。十四个接受者是由于在预先移植经期期间管理的 HBV 疫苗积极的 anti-HBs。肝活体检视在 10/14 anti-HBc negative/anti-HBs 被获得积极接受者并且在 4/9 anti-HBc 积极接受者。结果:在 46 个月的一个吝啬的后续时期以后,有保护的浆液 anti-HBs 层次的 1 个接受者作为有免疫力的逃跑 HBV 异种的后果得了 de novo HBV 感染。在 14 之中种牛痘的 anti-HBc negative/anti-HBs 积极接受者,有可得到的肝活体检视(10%) 的 1/10 病人在 13 瞬间有肝 HBV-DNA 没有浆液的肝以后的移植病毒的标记并且没得 de novo HBV 感染。种牛痘的 anti-HBc 没有 HBV 疫苗的反应的积极接受者是在浆液和肝积极的 HBV-DNA,病毒的 DNA 在下列测试是连续地否定的,自发的 seroconversion 因此被诊断。结论:由于 HBV 疫苗或过去的 HBV 感染的 anti-HBs 的存在似乎在保护从 anti-HBc 收到肝的病人有效积极施主。然而,有免疫力的逃跑 HBV 异种的出现,能躲避 anti-HBs 保护,应该被看作 HBV 感染的风险。 | Rafael Barcena Gloria Moraleda Javier Moreno M Dolores Martín Emilio de Vicente Jesús Nuo M Luisa Mateos Santos del Campo | 2006 | World Journal of Gastroenterology2006，12，13： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员